RxDoctor Payments Data

Tina Sorey

Optometrist · Jackson, MSNPI 1245213081

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,680 of the $7,755 with a category attached, or 73.2%. 17 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 25.0% of the total. Reporting peaked in 2023 at $2,411 and has fallen 61.3% since, to $934 in 2025. Among optometrist clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,755in general payments, 2019–2025

Across 267 payments — averaging $29.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$2K
  • Johnson & Johnson Vision Care, Inc.$2K
  • Alcon$994
  • Novartis$654
  • AbbVie$540
  • Mallinckrodt Hospital Products Inc.$456
  • plus $1K from 11 others

What the payments were for

  • Travel & lodging$2,06827%
  • Food & beverage$5,68073%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,755 in reported general payments places this provider in the 95th percentile of 372 optometrist providers in Mississippi.

See all optometrist providers in Mississippi

Medicare billing

Part B allowed, 2024
$63,360
Medicare patients
393
Services billed
740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast46$41,027
Loteprednol Etabonate20$1,815
Cyclosporine11$1,761
Prednisolone Acetate30$983
Latanoprost85$874
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$497
MoxifloxacinMoxifloxacin Hcl26$481
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha36$311
ErythromycinErythromycin Base21$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$1,939$41,02746 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$272$1,81520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 372 optometrist providers in Mississippi.

Other optometrist in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →